Bortezomib inhibits the proliferation of leukemic cells with AML1 S291fsX300 or AML1/ETO in vivo. (A) Schematic representation of the following experiments. Spleen cells isolated from S291fsX300-expressing leukemia mice were transplanted into sublethally irradiated (7.5 Gy) recipient mice. These mice were treated with twice weekly injections of vehicle or bortezomib. (B) Survival curves of mice transplanted with S291fsX300-induced leukemic cells treated with vehicle or bortezomib. Each group contains 12 mice. (C) Survival curves of mice transplanted with MLL/ENL-induced leukemic cells treated with vehicle or bortezomib. Each group contains 12 mice. The overall survival of mice in BM transplantation assays was analyzed by log-rank (Mantel-Cox) test. (D) Schematic representation of the following experiments. Luciferase positive SKNO-1 cells were injected into sublethally irradiated (2.0 Gy) NOG mice via tail vein, and these mice were treated with twice weekly injections of vehicle or bortezomib. (E-F) Tumor burden was quantified using in vivo bioluminescence imaging. Each group contains 3 mice.